Breaking News

Watson to Acquire Actavis

April 26, 2012

Expands international presence, generic injectable business

Watson Pharmaceuticals has entered into an agreement to acquire Actavis Group for approximately $5.6 billion, expanding its international presence as one of the world's biggest generic drug suppliers. The acquisition also enhances Watson's business in generic injectable cancer drugs. The transaction is expected to close in the fourth quarter.

Under the agreement, Watson will make an upfront payment of $5.6 billion. Actavis stakeholders are also eligible to receive a payment valued at $330 million during negotiations should Actavis achieve certain 2012 performance targets.

"In a single commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia," said Watson chief executive officer Paul Bisaro.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision